Doctors using the CADU system
Doctors using the CADU system - Experts at UCL and spinout company Odin Vision working with clinicians at UCLH have used artificial intelligence (AI) to help detect early signs of oesophageal cancer. The first procedure in the world using the AI technology was performed at University College Hospital by UCLH consultant gastroenterologist Dr Rehan Haidry. The system, called CADU, uses AI to support doctors in identifying cancerous tissue. CADU achieved regulatory approval at the start of 2021 making it the first medical device using AI for oesophageal cancer to be CE and UKCA approved for use on patients. It has been developed in collaboration with UCL scientists, including Dr Haidry, who is also Associate Professor at UCL, and Odin Vision, a spinout formed out of the research and innovation work at the UCL Wellcome / EPSRC Centre for Interventional and Surgical Sciences. Early signs of oesophageal cancer are difficult to diagnose. It has a five-year survival rate of less than 20% and is one of the six less survivable cancers.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
